Purpose:
To evaluate whether an incidentally noted splenic mass at abdominal computed tomography (CT) requires further imaging work-up.
Materials and Methods:
In this institutional review board-approved HIPAA-compliant retrospective study, a search of a CT database was performed for patients with splenic masses at CT examinations of the abdomen and chest from 2002 to 2008. Patients were divided into three groups: group 1, patients with a history of malignancy; group 2, patients with symptoms such as weight loss, fever, or pain related to the left upper quadrant and epigastrium; and group 3, patients with incidental findings. Patients' CT scans, follow-up examinations, and electronic medical records were reviewed. Final diagnoses of the causes of the masses were confirmed with imaging follow-up (83.9%), clinical follow-up (13.7%), and pathologic examination (2.4%).
Results:
This study included 379 patients, 214 (56.5%) women and 165 (43.5%) men, with a mean age 6 standard deviation of 59.3 years 6 15.3 (range, 21-97 years). There were 145 (38.3%) patients in the malignancy group, 29 (7.6%) patients in the symptomatic group, and 205 (54.1%) patients in the incidental group. The incidence of malignant splenic masses was 49 of 145 (33.8%) in the malignancy group, eight of 29 (27. 6%) in the symptomatic group, and two of 205 (1.0%) in the incidental group (P , .0001). The incidental group consisted of new diagnoses of lymphoma in one (50%) patient and metastases from ovarian carcinoma in one (50%) patient. Malignant splenic masses in the incidental group were not indeterminate, because synchronous tumors in other organs were diagnostic of malignancy.
Conclusion:
In an incidental splenic mass, the likelihood of malignancy is very low (1.0%). Therefore, follow-up of incidental splenic masses may not be indicated.
tertiary care center radiology department. This time period was specifically chosen to allow for sufficient clinical follow-up to establish benignity or malignancy of a mass. The search was consecutive, and CT reports were searched by using the keyword "spleen/splenic" plus one of the following terms: mass, lesion, nodule, abnormality, abscess, cyst, hemangioma, hamartoma, infarct, metastasis, lymphoma, sclerosing angiomatoid nodular transformation (SANT), and angiosarcoma. The inclusion criterion was the availability of adequate follow-up (imaging follow-up of 2 years, or clinical follow-up of 5 years for benign masses).
Masses that represented splenic infarcts and calcified granulomas and those that could not be confirmed at image review were excluded from the study. Examinations were performed with a variety of CT scanners from different vendors (GE, Fairfield, Conn; Siemens, Malvern, Pa; Toshiba, Glenn Mills, Pa) with one to 64 detectors. Because of the retrospective nature of our study and varied examination indications, CT protocols varied and included both intravenous contrast material-enhanced and unenhanced examinations. Where applicable, ioversol 320 (Optiray; Mallinckrodt, St Louis, Mo) was used as the intravenous contrast agent. The amount of administered contrast material varied according to patient weight: from the work-up of incidental findings through image-guided biopsy (5) or splenectomy (6) , including death from treatment of incidental abnormalities (7) .
The initial "white paper" from the American College of Radiology (ACR) incidental findings committee recommends further evaluation and/or follow-up imaging for all incidental splenic masses greater than 1 cm that do not have clearly benign features at imaging at the time of detection (4) . The majority of such solid splenic nodules and masses are benign, with hemangioma being the most frequent diagnosis (8, 9) . However, CT imaging characteristics of benign and malignant splenic masses often overlap, making definitive differentiation difficult (8, 10) . In addition, many CT examinations of the abdomen and pelvis are performed with intravenous contrast media only, which makes differentiation of enhancing nodules and masses from complex, proteinaceous, and/or hemorrhagic cysts impossible. Therefore, many patients require follow-up per ACR guidelines. While the ACR white paper represents a consensus opinion of experts in the field, the follow-up recommendations for splenic masses are based on personal experience of the expert panel, and the panel acknowledged that there were not enough scientific data on which to base this decision. The purpose of our study was, therefore, to evaluate whether an incidentally noted splenic mass at abdominal CT requires further imaging work-up.
Materials and Methods
Our retrospective study was Health Insurance Portability and Accountability Act-compliant and was approved by our institutional review board with a waiver of informed consent. We performed a search of our picture archiving and communications system database for patients diagnosed with a splenic mass or masses from throughout our institution (emergency oncology departments, inpatients and outpatients) performed during a 6-year time period (January 2002 to December 2008) in a large academic 
Implication for Patient Care
n Follow-up of splenic masses incidentally detected at CT (ie, in patients with no evidence of previous or newly diagnosed malignancy and no systemic symptoms or localized pain) does not appear to be indicated.
I ncidental masses at computed tomography (CT) of the abdomen and pelvis are very common, reported in 35%-56% of trauma patients who undergo CT (1, 2) . Such incidental findings include masses in the spleen, which have been reported as incidental findings in greater than 14% of autopsies (3), and most commonly represent hemangiomas, cysts, hamartomas, lymphangiomas, or granulomas. Incidental findings are defined as abnormalities that are not related to the patient's presenting illness, which, in the context of the spleen, would mean that the patient had no history of malignancy, no constitutional symptoms including fever and weight loss, and no symptoms related to the epigastrium or left upper quadrant of the abdomen.
The widespread use of cross-sectional imaging as an integral part of the diagnostic evaluation of patients with a variety of symptoms and concerns and the high spatial and contrast resolution of modern CT scanners have resulted in a marked increase in the number of such incidental findings (4). While the majority of these "incidentalomas" are benign, the possibility of incidental detection of a clinically important abnormality is real and occurs frequently in other organs, such as detection of a small renal cell carcinoma or an early lung cancer. Consequently, a decision must be made about whether, when, and how to work up an incidentally detected mass.
Ever-increasing pressure to control the cost of health care raises concerns regarding the fiscal burden of additional evaluation for all incidentalomas (4), particularly if the added value from additional imaging is questionable. Further concerns have been raised regarding unnecessary radiation, patient anxiety, and even patient injury resulting GASTROINTESTINAL IMAGING: Incidental Splenic Mass at CT: Does it Need Further Work-up?
Siewert et al and weight loss, and no symptoms related to the epigastrium or left upper quadrant of the abdomen. Final diagnosis of splenic masses was established by review of electronic medical records postdating the time of initial CT and correlation with either histopathologic results (obtained by means of surgical resection or percutaneous image-guided biopsy where applicable), imaging and clinical follow up, or clinical follow-up only in those patients for whom additional imaging was not performed or available. Clinical follow-up included review of physical examination and/or any clinical notes commenting on overall well-being of the patient. The initial determination was made by N.M. and K.S.; if a discordance with the CT report and electronic medical records was noted, the determination was then made in consensus with B.S.
For patients in the incidental and symptomatic groups, a mass was considered benign at follow-up imaging if it was stable or decreased in size or showed minimal annual growth of less than or equal to 2 mm per year (14) at follow-up imaging (CT, magnetic resonance [MR] imaging, ultrasonography [US], or fluorodeoxyglucose positron emission tomography [PET]/CT) throughout at least 2 years. In these groups, when only clinical follow-up was available, we required (a) a 5-year period without evidence of any malignancy for the splenic mass to be considered benign and (b) a persistent lack of symptoms in those with incidental masses and no change in or resolution of constitutional symptoms in those classified as symptomatic. Please note that patients who did not undergo imaging follow-up showing stability of the splenic mass for greater than or equal to 2 years or clinical follow-up notes greater than or equal to 5 years in our electronic medical records were excluded from our study. When none of these criteria were met, the splenic mass was considered malignant. In patients with a history of malignancy, a mass was considered malignant if it demonstrated an interval increase in the largest diameter of at least 10% features was followed up (ie, if a solid and a cystic mass were present, the solid mass was evaluated).
For all masses greater than 1 cm in maximum dimension, a region of interest (ROI) analysis was performed by placing circular ROIs centrally on unenhanced and contrast-enhanced acquisitions when available. A mass was considered a cyst if it was uniform in appearance and demonstrated attenuation measurements of less than or equal to 20 HU, was well circumscribed, and, where applicable, did not demonstrate enhancement with intravenous contrast material (11) . For all other masses, the presence or absence of contrast enhancement was recorded when applicable, with enhancement defined as an increase of greater than or equal to 20 HU between unenhanced and contrastenhanced acquisitions. Masses were categorized as indeterminate if attenuation measurements on unenhanced images were greater than 20 HU, and contrast-enhanced images were not available. Masses were classified as hematomas if they fulfilled previously published criteria (1, 12) , which included attenuation measurements greater than 50 HU on an unenhanced image that showed no enhancement; these were excluded from our study. Peripheral, wedge-shaped, low-attenuating masses were defined as infarcts (13) and were excluded from our study. Calcified granulomas were also excluded.
Electronic medical records were independently and blindly reviewed for the indication for the initial CT examination and for any documentation of malignancy in the clinical and pathologic notes predating the time of the initial CT. Patients were stratified into three groups according to clinical history and presentation as follows: group 1 (malignancy), patients with a history of prior malignancy or currently undergoing treatment of a known malignancy; group 2 (symptomatic), no history of malignancy, but constitutional symptoms including weight loss, fever, or pain related to the left upper quadrant and epigastrium; and group 3 (incidental), no history of malignancy, no constitutional symptoms such as fever 120 mL of contrast material for patients who weighed less than or equal to 120 lbs and 150 mL of contrast material for those who weighed more than 120 lbs. Injection rates ranged from 2 mL/sec for general examination of the abdomen to 5 mL/sec for CT angiography. Depending on the protocol, bolus tracking was used to allow for optimal contrast opacification with contrast-enhanced CT or a fixed 75-second delay for routine imaging in the portal-venous phase. Section thickness for all CT examinations was 2-5 mm.
Retrospective review was performed of the initial CT examination that demonstrated the splenic mass or masses and any subsequent relevant follow-up examinations performed during the time period of 2002-2013. Subsequent follow-up examinations, CT and related imaging reports, and electronic medical records were reviewed by three investigators: (N.M. and K.S., who were undergoing abdominal imaging fellowship training, and B.S., with 19 years of experience in abdominal imaging). CT image analysis was performed blinded with respect to patient outcome before review of each patient's medical record. The following CT findings were recorded: size of the mass or masses at initial and follow-up imaging, number of splenic masses, and presence or absence of enhancement on images of patients who were administered intravenous contrast material.
Mass size was remeasured in two perpendicular planes on axial images including the largest axial dimension. Measurements incorporated the entire mass, inclusive of solid components and components believed to be cystic. Annual growth rate of the largest mass in the initial examination was calculated by measuring the largest diameter at follow-up imaging minus the largest diameter at the initial examination and then dividing the result by the number of years between follow-up examinations.
If multiple masses were present, with a similar appearance at initial CT, the largest mass was followed up. When multiple dissimilar masses were present in the spleen at initial CT, the mass with the most complex imaging 
Results
During the time of our study (January 2002 to December 2008), we identified 477 consecutive patients who met our search criteria for an incidental splenic mass at CT (Fig 1) . Ninety-eight (20.5%) patients were excluded: 80 (81.6%) There were 145 of 379 (38.3%) patients in the malignancy group, 29 of 379 (7.6%) patients in the symptomatic group, and 205 of 379 (54.1%) patients in the incidental group. The incidence of malignant splenic masses was 49 of 145 (33.8%) in the malignancy group 379 masses, 87 (23.0%) were less than 1 cm in size, and 292 of 379 masses were greater than or equal to 1 cm in size (77.0%). Two hundred thirty eight of 292 (81.5%) masses greater than or equal to 1 cm were not cystic.
Follow-up imaging was available for 348 of 379 (91.8%) patients. In 318 of 348 patients, imaging follow-up was used to establish the final diagnosis. In 30 of 348 patients, imaging follow-up was available, but was performed within less than 24 months, a time period too short to establish a final diagnosis; therefore, clinical follow-up of greater than or equal to 5 years was used to establish a final diagnosis. No discrepancies were found between follow-up imaging results that met criteria for a benign splenic mass and subsequent clinical follow-up results for an individual patient. At follow-up imaging ( Table 1 Final Diagnosis of Splenic Masses 
Patients with History of Malignancy
One hundred forty-five patients had a history of malignancy consisting of the following tumors: gastrointestinal tract (n = 26), lymphoma or leukemia (n = 25), breast (n = 21), melanoma (n = 15), lung (n = 14), other (endometrial, carcinoid, squamous cell carcinoma, liposarcoma, bladder, mesothelioma, testicular [n = 14]), hepatobiliary or pancreatic (n = 11), renal cell carcinoma (n = 9), ovarian (n = 6), and prostate (n = 4). Two patients had a history of both lymphoma and breast cancer, and these are included in the group of patients with lymphoma. Of the 49 patients in this group found to have malignant splenic masses, the distribution of primary malignancies was as follows: lymphoma (n = 13), melanoma (n = 11), gastrointestinal tract (n = 6), lung (n = 4), other (endometrial, carcinoid and squamous cell carcinoma [n = 4]), breast (n = 4), ovarian (n = 3), hepatobiliary (n = 2), and renal (n = 2) (Fig 3) . The frequency of splenic involvement with metastatic disease was as follows: melanoma, 73% (11 of 15); lymphoma, 52% (13 of 25; one patient GASTROINTESTINAL IMAGING: Incidental Splenic Mass at CT: Does it Need Further Work-up?
Siewert et al and ovarian cancer) were established prospectively on the basis of their CT examinations and were confirmed at splenectomy and exploratory laparoscopy with total hysterectomy, bilateral salpingo-oophorectomy, and tumor debulking. One patient with a solid mass showed a rapid increase in mass size and a second patient had a new large mass and underwent splenectomy. These were both found to represent SANT at histopathologic evaluation (Fig 8) , a rare, benign vascular neoplasm.
Discussion
The clinical importance of splenic masses noted at CT examination of the abdomen in patients without a history of malignancy is unknown (16) , to our knowledge, and the ACR white paper, published in 2013, therefore, recommends follow-up for all noncystic splenic masses larger than 1 cm (4). We conclude from our study that characterization and follow-up of an incidentally noted splenic mass at CT in a patient with no history of malignancy and with no constitutional symptoms or left upper-quadrant pain is not indicated, regardless of mass size. Malignant masses were identified in only 1.0% (two of 205) of incidental splenic masses in our study. Even when we excluded masses that meet criteria for cysts from this group, these two patients represented only 1.1% be malignant, with the final diagnosis of lymphoma in all eight (Fig 4) . Six of eight (75%) patients had concomitant extensive lymphadenopathy involving one to three of the following lymph node stations: the retroperitoneum (n = 3), inguinal (n = 2), perisplenic (n = 2), porta hepatis (n = 2), peripancreatic (n = 1), celiac axis (n = 1), and portocaval (n = 1). Confirmation of lymphoma was made by means of splenectomy (n = 4), response to chemotherapy (n = 3), and CT-guided biopsy (n = 1). In two of eight (25%) patients, the spleen was the only organ involved ( Fig 5) .
Patients with Incidental Splenic Masses
Two hundred five of 379 (54.1%) patients with splenic masses had no history of malignancy and no fever, weight loss, or symptoms related to the left upper quadrant or epigastrium. The splenic masses were, therefore, considered incidental. Two of 205 (1.0%) masses were determined to be malignant (the clinical indication for these two CT examinations were hematuria and abdominal pain with vomiting). One malignant mass consisted of a new diagnosis of lymphoma in a patient with perisplenic lymphadenopathy (Fig 6) . The other patient had a new diagnosis of metastatic ovarian carcinoma with metastases simultaneously found in the pleura, omentum, inguinal nodes, and subcutaneous soft tissues (Fig 7) . In these patients, both diagnoses (ie, lymphoma also had breast cancer); ovarian carcinoma, 50% (three of six); lung, 29% (four of 14); gastrointestinal tract, 23% (six of 26); renal cell carcinoma, 22% (two of nine); hepatobiliary or pancreatic, 18% (two of 11); breast, 19% (four of 21); and other, 29% (four of 14) . No metastases were seen in patients with prostate cancer.
All patients (36 of 36, 100%) with metastatic masses (other than lymphoma) in the spleen had concomitant metastatic disease in other organs based on imaging results. The number of additional organs involved when splenic metastases were present was as follows: none (n = 0), one other organ (n = 6), two other organs (n = 22), three other organs (n = 6), and four other organs (n = 2). In other words, in 30 of 36 (83.3%) patients with splenic metastases, at least two other organs harbored metastases, making the spleen the third most likely organ to be involved. In only six of 36 (16.7%) patients with splenic metastases was the spleen and only one other organ involved. In no patient was the spleen the sole site of metastatic disease.
Symptomatic Patients
Twenty-nine of 379 (7.6%) patients had no history of malignancy, but presented with constitutional symptoms or symptoms related to the left upper quadrant and were found to have splenic masses. In eight of 29 (27.6%) patients, the splenic masses proved to Siewert et al no history of malignancy were found to be benign. The authors concluded similarly that follow-up is not necessary, even if the adrenal findings are indeterminate with the use of CT criteria. The ACR white paper currently recommends follow-up for all noncystic splenic masses greater than 1 cm that do not have clearly benign features at imaging at the time of detection (4). These guidelines would have led to follow-up imaging or MR imaging evaluation of 151 of 266 (56.8%) masses larger than 1 cm in our series. Thut et al (19) recently suggested further were only found in 0.6% (2 of 337) of isolated splenic masses and were only seen in the group of patients with constitutional symptoms. This further supports our claim that the isolated and incidentally found splenic mass is of unlikely clinical significance, regardless of its appearance.
Our findings regarding the importance of incidental masses in the spleen are in concordance with work by Song et al (18) on incidental adrenal nodules and masses detected at CT (18) . In this study, all of 1049 incidentally noted adrenal nodules and masses in patients with (two of 169) of this patient group. Also in both of these patients, the splenic masses were neither isolated nor indeterminate findings, because CT demonstrated disease in other locations, leading to the prospective diagnosis of a malignant splenic mass. Therefore, with an isolated incidental splenic nodule or mass, follow-up or further workup does not seem to be indicated.
Malignant, isolated splenic masses can occur but are extremely rare. While lymphoma and angiosarcoma (17) can present this way, the latter is very rare. In our study, isolated malignant masses Images in a 78-year-old man who presented with diarrhea and weight loss. Axial CT images of abdomen and pelvis acquired with oral and intravenous contrast material raised concern for new diagnosis of lymphoma because of (a) hypoattenuating mass in spleen (white arrow), extensive thickening of stomach wall (black arrow), and soft-tissue masses adjacent to left hepatic lobe (dashed black arrow), posterior to right hepatic lobe (white arrowhead), and adjacent to spleen (black arrowheads); (b) masses in adrenals (white arrows) and soft-tissue nodules posterior to right kidney (black arrows); (c) retroperitoneal lymphadenopathy (black arrows); and (d) large pelvic mass from extensive bowel wall thickening (black arrows). Pelvic mass caused bilateral hydronephrosis (white arrows in c) from compression of distal ureters. Diffuse anasarca (white arrows in d) is noted. pain, splenomegaly, or anemia. Symptoms occur when lesions enlarge and cause mass effect: stretching the splenic capsule. Our findings challenge the ACR recommendation for patients in whom a splenic mass is truly incidental. Further confirmation of our findings in a multicenter study incorporating a larger series of patients would be helpful to validate this approach.
A different approach for the workup of splenic masses is warranted in patients with constitutional symptoms, because eight of 29 (27.6%) splenic masses in patients with such symptoms were found to be malignant in our series, all of which were confirmed to be lymphoma. In 75% of these cases, lymphadenopathy was identified at multiple other sites, and the diagnosis of lymphoma was made prospectively. In 25% of patients with a new diagnosis of lymphoma and constitutional symptoms, the spleen was the only organ involved with lymphoma. In both patients, these were large, solid splenic masses (7 cm and 10 cm), with an appearance highly suspicious for cancer. Therefore, in patients with constitutional symptoms and isolated, indeterminate, or enhancing splenic masses, the possibility that such a mass is malignant is small (6.9%) but not negligible. MR imaging can be used to differentiate benign from malignant masses in 72% (10 of 14) of cases (22) , and Metser et al (23) demonstrated even better results in our incidental group: follow-up was recommended for an incidental splenic mass detected at CT urography performed for hematuria. Follow-up CT demonstrated interval growth at a rate faster than that expected of hemangiomas (14) , which led to splenectomy. Pathologic evaluation demonstrated SANT, a benign tumor (21) . Patients with SANT are only rarely symptomatic (three of nine, 37%) with abdominal MR imaging evaluation of all complex/ solid splenic masses, while other authors have proposed image-guided biopsy in certain clinical scenarios with nonspecific imaging features (20) . Such a practice would increase health care costs and potentially expose patients to increased morbidity and mortality (7) . An example of patient morbidity resulting from such a follow-up recommendation is illustrated by one patient Axial CT image of abdomen acquired with oral and intravenous contrast material demonstrates splenic mass (black arrow) and perisplenic lymphadenopathy (white arrows), raising concern for lymphoma. This was confirmed at splenectomy. (25) . In addition, all patients with metastatic disease to the spleen always had more than one site of disease in the abdomen and pelvis (ie, the spleen was never the only organ involved in metastases). In most patients (30 of 36; 83.3%), at least two other organs to one of these groups, and we do not believe it is warranted in asymptomatic patients with incidental findings. In our series, even in patients with a history of malignancy, only 33.8% of splenic masses represented metastases, which is a result that is in agreement with those of other studies (24) . The majority of these malignant masses were from metastatic disease (73.5%), in which the primary tumors consisted for PET/CT, with sensitivity and specificity of 100% for malignant and 100% and 80% for benign masses, with a negative predictive value of 100%. These authors suggest that further evaluation with MR imaging or PET/CT should be considered as the next step in diagnosis. Although we agree with this approach in patients with constitutional symptoms or a history of malignancy, most patients in the study group of Dhyani et al (22) Axial CT images of abdomen and pelvis with oral and intravenous contrast material raised concern for malignancy: (a) epiphrenic lymphadenopathy (white arrow), pericardial effusion (black arrow), and left pleural effusion (arrowhead); (b) splenic mass (arrow) and extensive ascites; In addition, our study was focused on assessing size stability. Finally, comparison of mass size among modalities and between examinations obtained with different CT scanners is accepted in daily clinical practice; therefore, we feel that these results are relevant to general practice. A third limitation may be a lower incidence of splenic masses in our population due to our search of reports for splenic masses rather than performing image analysis, which may have resulted in identification of more masses. As CT examinations were performed over a long time interval, some examinations had been performed with older technology, and more modern equipment and protocols probably would have increased the yield for incidental splenic findings. We point out that although infectious processes such as microabscesses may represent another class of incidental masses, we did not encounter any infectious splenic processes in our study population of 379 masses. A of a study on hepatic hemangiomas found that 40% of hemangiomas increased in a linear fashion at a rate of up to 2 mm per year (14) . In our series, 18 of 165 (10.9%) benign, enhancing masses demonstrated a similar size increase. Two indeterminate masses demonstrated more than 2 mm of annual growth and were therefore resected. Pathologic evaluation revealed a diagnosis of SANT, a benign tumor, further indicating that interval growth of a splenic mass of greater than 2 mm per year need not indicate a malignant origin. Therefore, if anything, our lack of pathologic proof may have allowed overestimation of the incidence of a malignant splenic mass in the group of patients with known malignancy. This possible overestimation is compounded by our use of decrease in size after systemic chemotherapy as an indicator of malignancy in this patient group: decrease in size was noted in 21.9% of benign masses in our series, with 2.1% of benign masses resolving completely.
Other limitations due to the retrospective nature of our study were the variability in CT scanners and imaging protocols and the use of different imaging modalities for follow-up. This creates inherent differences in mass harbored metastases, and in only six of 36 patients with splenic metastases (16.7%) was the spleen and one other abdominal or pelvic organ involved. This was concordant with results in the reported literature (12) .
A limitation of our study was the infrequent availability of pathologic diagnosis (nine of 379 cases, 2.4%). The etiology of our indeterminate benign masses is therefore unclear, although hemangiomas and hamartomas are expected to be represented in this group (26, 27) . However, size stability over two years as indicative of benignity has also been used as a criterion by other investigators (22) and is used and accepted for incidentally discovered masses in other anatomic sites (28) .
The absence of pathologic proof is even more complicated for patients with a history of malignancy in whom the definitive histologic diagnosis of a focal splenic mass is seldom obtained but rather assumed to be malignant on the basis of an increase in size over time or a size decrease in response to chemotherapy (29) . We considered any solid mass in the malignancy group that increased in size as malignant. However, assuming a size increase implies malignancy may be inaccurate. Authors 
